Centanafadine

Summary

Centanafadine (CHEMBL3301621) is a phase-3 clinical-stage small molecule; indicated across 4 conditions including attention deficit-hyperactivity disorder and eating disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 4 conditions
• Clinical trials: 12
• Chemistry: 209.29 Da · C15H15N

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3301621
Name	Centanafadine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	16095349
Molecular formula	C15H15N
Molecular weight	209.29
InChIKey	HKHCSWPSUSWGLI-CABCVRRESA-N

SMILES: C1[C@H]2[C@@]1(CNC2)C3=CC4=CC=CC=C4C=C3

IUPAC name: (1R,5S)-1-naphthalen-2-yl-3-azabicyclo[3.1.0]hexane

Also known as: Centanafadina, Centanafadine, DOV 216,419, DOV 216,419 free base, DOV-216419, EB-1020, EB-1020 free base, CENTANAFADINE

Parent form; salt/anhydrous children: CHEMBL3301615

Patent coverage: 53 distinct patent families (187 SureChEMBL compound mentions), from 2 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Sodium-dependent noradrenaline transporter, Sodium-dependent serotonin transporter, Sodium-dependent dopamine transporter.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SLC6A2	8	IC50	10	nM	CHEMBL_ACT_29194894
SLC6A3	7.22	IC50	60	nM	CHEMBL_ACT_29194903

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
attention deficit-hyperactivity disorder	3	MONDO:0007743	EFO:0003888
eating disorder	2	MONDO:0005451	EFO:0005203
major depressive disorder	2	MONDO:0002009	MONDO:0002009

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 12.

Phase distribution

Phase	Trials
PHASE1	6
PHASE2	4
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05428033	PHASE3	COMPLETED	A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)
NCT06973577	PHASE3	COMPLETED	P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
NCT04081363	PHASE2	COMPLETED	Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD)
NCT05066724	PHASE2	COMPLETED	Efficacy of Centanafadine SR as a Potential Smoking Cessation Treatment
NCT05113953	PHASE2	COMPLETED	A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder
NCT05536414	PHASE2	COMPLETED	Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder
NCT01744808	PHASE1	COMPLETED	A Study to Evaluate the Safety, Tolerance, and Pharmacokinetic and Pharmacodynamic Profile Of 1 SR Formulation of EB-1020
NCT02144415	PHASE1	COMPLETED	A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users
NCT04398225	PHASE1	COMPLETED	A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine in Pediatric Subjects With Attention-deficit/Hyperactivity Disorder
NCT04786730	PHASE1	COMPLETED	A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder
NCT07314333	PHASE1	COMPLETED	A Trial to Assess How Centanafadine Interacts With Stimulants in the Body
NCT07486895	PHASE1	COMPLETED	Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).